Alternative NamesBrain-derived neurotrophic factor; Abrineurin; proBDNF;
Application(s)ELISA, IHC-Frozen, Neutralize, WB
Antibody HostRabbit
Antibody TypePolyclonal
SpecificityLess than 0.1% cross-reactivity against NGF, recombinant NT3 and NT4 by dot blot. This antiserum is known to react with BDNF from rat, mouse and human. Expected to react with BDNF of other species due to amino acid sequence homology.
Species ReactivityHuman, Mouse, Other Mammals (Predicted), Rat
Application DetailsIHC, ELISA (1 site), Western Blot, immunoblot, inhibition of biological activity in vitro/in vivo. Recommended to be used at an amount of 1-10 µg/mL for immunohistochemistry, Western blot or immunoblot, 0.1 µg/mL for ELISA and for inhibition of biological activity in vitro 1-10 µg/mL. Use neat for in vivo studies at 2-10 µg/mL (ED50). This antiserum stains cell bodies and some nerve terminals in the dorsal horn of the rat spinal cord, however, does not stain finest nerve terminals. Western blot: 1-10 µg/mL. Tissue homogenate is a recommended sample application for Western Blotting. The antibody detects 14 kDa (mature BDNF), 32 kDa (proBDNF) and a 18 kDa BDNF isoform, however numerous other non-characterized bands may also be present. In cell lysates, only 18 kDa and 32 kDa BDNF are detected. Alternative antibodies for Western Blotting are: R-1707-100 (cell lysates and tissue homogenates), R-083-100/R-066-500 (cell lysates, tissue homogenates and human serum); M-1744-50/100 (human serum and tissue homogenates).
Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
TargetBrain-derived neurotrophic factor (BDNF)
SpecificityLess than 0.1% cross-reactivity against NGF, recombinant NT3 and NT4 by dot blot. This antiserum is known to react with BDNF from rat, mouse and human. Expected to react with BDNF of other species due to amino acid sequence homology.
Target Host SpeciesHuman
Species ReactivityHuman, Mouse, Other Mammals (Predicted), Rat
Antibody HostRabbit
Antibody TypePolyclonal
Antibody IsotypeIgG
ConjugateUnconjugated
Immunogen DescriptionRecombinant human BDNF
Purity DescriptionProtein G purified IgG
FormatLyophilized
Reconstitution InstructionsSpin vial briefly before opening. Reconstitute in 500 µL sterile-filtered 1X PBS, pH 7.2-7.6. Centrifuge to remove any insoluble material.
Storage InstructionsAfter reconstitution keep aliquots at -20°C for a higher stability, and at 2-8°C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesBrain-derived neurotrophic factor; Abrineurin; proBDNF;
Scientific BackgroundBDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. Microglia release BDNF that may contribute to neuroinflammation and neuropathic pain. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Western blot analysis of BDNF expression in SH-SY5Y cell lysate (RIPA) and human brain. Polyclonal rabbit antibodies to rhBDNF R-088-100 (whole serum, 1:1000) and R-017-500 (IgG, 10 µg/mL) detect monomeric BDNF at 14 kDa in human brain (Tris-homogenate). ProBDNF is detected at the expected molecular weight of 32 kDa for glycosylated proBDNF monomer. A 18 kDa BDNF-isoform is shown that has previously been detected with other BDNF antibodies (Tongiorgi et al., 2012; Silhol et al., 2007). This 18 kDa band is also visible in the proBDNF protein sample, Lane 2. Western Blotting Method: SDS-PAGE: denaturing and reducing, 12% Bis-Tris gel; Transfer: Tris-Glycine buffer, semi-dry transfer; Membrane: nitrocellulose (0.22 µm); Blocking: 5% skim milk in TBST, 1 hour at RT; Primary antibody: overnight at 4°C; Secondary antibody: anti-rabbit-HRP (1/6000), 2 hours at RT; Detection: Chemiluminiscence.
Immunohistochemical staining for BDNF in rat dorsal root ganglion (DRG) using Rabbit antibody to rh BDNF: IgG (R-017-500) at an amount of 5 µg/mL. Neuron cell bodies are strongly stained for BDNF.
Specific ReferencesSerra, M.P. et al. (2022) Anti-Inflammatory Effect of Beta-Caryophyllene Mediated by the Involvement of TRPV1, BDNF and trkB in the Rat Cerebral Cortex after Hypoperfusion/Reperfusion Int. J. Mol. Sci. Mar; 23(7),3633
Lin J.C-Y. and Rosenthal A. (2011) Methods for treating obesity by administering a trkB antagonist US Patent US 7935342 B2
Counts S.E. and Mufson E.J. (2010) Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity J Neurochem. 2010 May;113(3):649-60.
Unsain N. et al (2009) Brain-derived neurotrophic factor facilitates TrkB down-regulation and neuronal injury after status epilepticus in the rat hippocampus J Neurochem. 2009 Oct;111(2):428-40
Salehi Z., Mashayekhi F. (2009) Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease J Clin Neurosci. Jan;16(1):90-3.